Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Moroney

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
ESC Heart Failure|April 11, 2023
Impact of diabetes duration on left ventricular mass regression with empagliflozinMichael Moroney, Raj Verma, Makoto Hibino, et al.
ESC Heart Failure|April 11, 2023
Baseline neutrophil-to-lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodellingRaj Verma, Michael Moroney, Makoto Hibino, et al.
The Annals of Thoracic Surgery|January 31, 2025
Emerging Implications of Elevated Lipoprotein(a) Levels in Coronary Artery Bypass Graft SurgeryShubh K Patel, Miriam S Badross, Nitish K Dhingra, et al.
European Journal of Heart Failure|November 25, 2025
Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programmeAmbarish Pandey, Michael Moroney, Subodh Verma, et al.
Cardiovascular Research|August 29, 2025
Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational studyMichael Moroney, Jack H Casey, Hwee Teoh, et al.
Circulation|November 6, 2022
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical TrialKim A Connelly, C David Mazer, Pankaj Puar, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
ESC Heart Failure|April 11, 2023
Impact of diabetes duration on left ventricular mass regression with empagliflozinMichael Moroney, Raj Verma, Makoto Hibino, et al.
ESC Heart Failure|April 11, 2023
Baseline neutrophil-to-lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodellingRaj Verma, Michael Moroney, Makoto Hibino, et al.
The Annals of Thoracic Surgery|January 31, 2025
Emerging Implications of Elevated Lipoprotein(a) Levels in Coronary Artery Bypass Graft SurgeryShubh K Patel, Miriam S Badross, Nitish K Dhingra, et al.
European Journal of Heart Failure|November 25, 2025
Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programmeAmbarish Pandey, Michael Moroney, Subodh Verma, et al.
Cardiovascular Research|August 29, 2025
Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational studyMichael Moroney, Jack H Casey, Hwee Teoh, et al.
Circulation|November 6, 2022
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical TrialKim A Connelly, C David Mazer, Pankaj Puar, et al.
Pageof 1